GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beijing Leadman Biochemistry Co Ltd (SZSE:300289) » Definitions » Return-on-Tangible-Equity

Beijing Leadman Biochemistry Co (SZSE:300289) Return-on-Tangible-Equity : -0.69% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Leadman Biochemistry Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Beijing Leadman Biochemistry Co's annualized net income for the quarter that ended in Mar. 2024 was ¥-10.8 Mil. Beijing Leadman Biochemistry Co's average shareholder tangible equity for the quarter that ended in Mar. 2024 was ¥1,568.0 Mil. Therefore, Beijing Leadman Biochemistry Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -0.69%.

The historical rank and industry rank for Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity or its related term are showing as below:

SZSE:300289' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -4.95   Med: 2.67   Max: 17.93
Current: 0.28

During the past 13 years, Beijing Leadman Biochemistry Co's highest Return-on-Tangible-Equity was 17.93%. The lowest was -4.95%. And the median was 2.67%.

SZSE:300289's Return-on-Tangible-Equity is ranked worse than
52.17% of 759 companies
in the Medical Devices & Instruments industry
Industry Median: 1.4 vs SZSE:300289: 0.28

Beijing Leadman Biochemistry Co Return-on-Tangible-Equity Historical Data

The historical data trend for Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Leadman Biochemistry Co Return-on-Tangible-Equity Chart

Beijing Leadman Biochemistry Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.58 -4.95 1.72 -3.58 0.99

Beijing Leadman Biochemistry Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.16 2.12 1.87 -2.15 -0.69

Competitive Comparison of Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity

For the Medical Devices subindustry, Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity falls into.



Beijing Leadman Biochemistry Co Return-on-Tangible-Equity Calculation

Beijing Leadman Biochemistry Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=15.337/( (1533.868+1569.241 )/ 2 )
=15.337/1551.5545
=0.99 %

Beijing Leadman Biochemistry Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-10.82/( (1569.241+1566.694)/ 2 )
=-10.82/1567.9675
=-0.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Beijing Leadman Biochemistry Co  (SZSE:300289) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Beijing Leadman Biochemistry Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Beijing Leadman Biochemistry Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Leadman Biochemistry Co (SZSE:300289) Business Description

Traded in Other Exchanges
N/A
Address
No.5 Hongda South Road, Beijing, CHN
Beijing Leadman Biochemistry Co Ltd is a biotechnology company based in China. The company is focusing on research and development, manufacture, and sales of in vitro diagnostic (IVD) products. The company has core competencies in biochemistry, in vitro diagnostic reagents and instruments. Its product offering includes biochemical raw materials such as enzymes, coenzymes, antibodies, buffers, and enzyme substrates; biochemistry diagnostic and companion reagents; and medical test instruments.
Executives
Ding Yao Liang Executives
Wang Xiao Hong Supervisors
Zhang Hai Tao Executives
Zhang Ya Li Supervisors
Sun Qian Director
Wang Jian Hua Directors, executives
Wang Yi Xing Directors, executives
Yang Lu Ping Securities Affairs Representative
Niu Ju Hui Secretary Dong
Zhang Kun Director
Shen Guang Qian Directors, executives
Ma Yan Wen Director
Wang Lan Zhen Directors, executives

Beijing Leadman Biochemistry Co (SZSE:300289) Headlines

No Headlines